AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm is reminding purchasers of Aardvark Therapeutics securities of an October 13, 2026 lead plaintiff deadline in a previously filed securities fraud class action. The class period covers the February 13, 2025 IPO through May 14, 2026. The suit alleges defendants made materially false and misleading statements, failing to disclose that ARD-101 was less safe than represented and overstating the drug's clinical, regulatory, and commercial prospects.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.